Pay-for-delay settlements fall for second year: FTC report

Pharmaceutical companies have entered into fewer potential ‘pay-for-delay’ patent settlements for the second year in a row, following the US Supreme Court’s decision in FTC v Actavis.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

‘Considerable increase’ in pay-for-delay settlements: FTC report

24 May 2019 The number of ‘pay-for-delay’ patent settlements reached in fiscal year 2016 represented a “considerable increase” from the previous year, according to a Federal Trade Commission report released yesterday, May 23, though there has been a considerable reduction in the most problematic settlements since 2013.

Americas

US FTC settles pay-for-delay case with AbbVie

1 March 2019 The US Federal Trade Commission concluded a ten-year pay-for-delay suit yesterday, with AbbVie agreeing not to enter certain settlements in patent cases that delay market entry of generic drugs.

Europe

Pay-for-delay settlements remain steady in EU

13 March 2018 The number of ‘pay-for-delay’ patent settlements in the EU has “stabilised at a low level”, according to the European Commission.